Taking Ozempic or Wegovy? What Two Eye-Safety Studies Suggest

Ozempic and Wegovy are widely recognized GLP-1 medications. Both contain semaglutide, but they have different approved uses. Ozempic is used primarily to treat Type 2 diabetes, while Wegovy is approved for chronic weight management in eligible patients and for reducing certain cardiovascular risks.

Recent reports have raised questions about two possible eye-related problems among people taking GLP-1 medications:

1. A rare form of vision loss called nonarteritic anterior ischemic optic neuropathy (NAION).
2. Eye changes that may resemble or worsen diabetic retinopathy, particularly when blood sugar improves rapidly.

These reports describe possible associations, not proven cause-and-effect relationships. The available coverage does not provide enough information about the studies’ sample sizes, comparison groups, follow-up periods, or exact risk estimates. The reports therefore do not prove that Ozempic or Wegovy cause blindness or permanent eye damage.

Do not stop Ozempic, Wegovy, or another prescribed medication without speaking with the prescribing clinician. Sudden vision changes require prompt medical evaluation.

What Are Ozempic, Wegovy, and GLP-1 Drugs?

Ozempic and Wegovy contain semaglutide, which imitates the naturally occurring hormone glucagon-like peptide-1 (GLP-1). Semaglutide can:

• Increase insulin release when blood glucose is elevated.
• Reduce the release of glucagon, a hormone that raises blood sugar.
• Slow stomach emptying.
• Reduce appetite.
• Support weight loss when used as part of an appropriate treatment plan.

The medication is administered by injection on a schedule prescribed by a clinician. Doses typically increase gradually to reduce side effects, although the exact plan depends on the product, indication, and patient.

Other GLP-1 medications contain different active ingredients, including liraglutide, dulaglutide, and exenatide. Findings involving semaglutide should not automatically be applied to every medication in the GLP-1 class.

Why Ozempic and Wegovy Are Prescribed

Ozempic is approved for adults with Type 2 diabetes. It can improve blood sugar control and, in certain patients, reduce the risk of major cardiovascular events.

Wegovy is approved for chronic weight management in eligible adults and adolescents. It may also reduce the risk of major cardiovascular events in some adults with overweight or obesity and established cardiovascular disease.

Although the products contain the same active ingredient, they have different approved indications, doses, and prescribing criteria. A safety finding involving one dose or patient population may not apply equally to another.

Common Side Effects and Serious Warning Signs

Common side effects of Ozempic and Wegovy include:

• Nausea.
• Vomiting.
• Diarrhea.
• Constipation.
• Reduced appetite.
• Abdominal discomfort.

These effects often occur during dose increases and may improve over time. Severe vomiting or diarrhea can cause dehydration and additional health risks.

Sudden vision loss, a new blind spot, flashes, a curtain-like shadow, or major visual distortion should not be dismissed as a routine medication side effect.

Study One: A Reported Link to Rare Vision Loss

What Is NAION?

ABC News reported a potential connection between GLP-1 medications and nonarteritic anterior ischemic optic neuropathy, commonly called NAION (Source 3).

NAION occurs when blood flow to part of the optic nerve is disrupted. The optic nerve carries visual information from the eye to the brain. Damage can cause vision loss, usually in one eye.

Possible symptoms include:

• Sudden, painless vision loss in one eye.
• A dim or blurry area in the visual field.
• Difficulty seeing the upper or lower part of an image.
• A new missing area in the field of vision.

Symptoms may be noticed after waking. Severity varies, and only an eye-care professional can determine the cause.

What the Reported Research May Show

The available report indicates that researchers examined a possible association between GLP-1 medications and NAION. However, the supplied source does not provide the study’s full methods, participant number, control group, follow-up period, or absolute risk.

That missing information matters. A study can show that two events occur in the same group without proving that one caused the other.

Potential confounding factors include:

• Type 2 diabetes.
• High blood pressure.
• Sleep apnea.
• Older age.
• Cardiovascular disease.
• Kidney disease.
• Smoking.
• Existing optic-nerve problems.
• Other medications.

People taking GLP-1 drugs may also be more likely to have several of these risk factors, making it difficult to separate the effects of the medication from those of underlying disease.

NAION is uncommon or rare compared with routine gastrointestinal side effects. The available summary does not provide a verified absolute-risk estimate. Until the original study details and current regulatory guidance are reviewed, the safest conclusion is that this possible signal requires further investigation. It does not establish that semaglutide causes NAION.

Study Two: Possible Changes Resembling Diabetic Retinopathy

A separate report examines whether GLP-1 medications may be associated with eye problems resembling diabetes-related complications (Source 7).

The supplied source does not identify the study design, participant population, or confirmed outcome. It should therefore be treated as a description of a research question, not proof of a new medication complication.

What Is Diabetic Retinopathy?

Diabetic retinopathy develops when prolonged high blood sugar damages small blood vessels in the retina, the light-sensitive tissue at the back of the eye.

Early disease may cause no symptoms. As it progresses, damaged vessels can leak fluid or blood. Advanced retinopathy may cause:

• Blurred vision.
• Retinal swelling.
• New floaters.
• Dark areas in the visual field.
• Retinal scarring.
• Severe or permanent vision loss.

People with diabetes already face an elevated risk of eye disease before starting Ozempic or another GLP-1 medication. That underlying risk must be considered when evaluating vision problems during treatment.

Rapid Blood Sugar Improvement

Rapid improvement in blood glucose has been associated with temporary worsening of diabetic retinopathy in some patients. This does not necessarily mean that the medication directly damages the retina.

Patients with severe or untreated retinopathy may be more vulnerable when glucose levels change quickly. Clinicians may monitor patients more closely when they have existing retinopathy, poorly controlled diabetes, a high starting A1C, previous laser treatment or eye injections, rapid glucose changes, or several diabetes medications changed at once.

This does not mean that patients with diabetic retinopathy cannot use semaglutide. Treatment and eye monitoring should be individualized.

Important questions remain unanswered, including whether risk differs between Ozempic and Wegovy doses, whether the potential association applies to other GLP-1 drugs, whether any effect is temporary or permanent, and which patients face the greatest risk. Large controlled studies, clinical-trial analyses, eye examinations, and post-marketing surveillance can help clarify these issues.

Do Ozempic or Wegovy Cause These Problems?

A medication can be associated with an outcome without being proven to cause it. Observational studies, medical-record reviews, and adverse-event reports can identify potential safety signals, but they may not control for every difference between people who take a medication and those who do not.

GLP-1 users may have diabetes-related vascular damage, obesity-related sleep apnea, high blood pressure, kidney disease, cardiovascular disease, or changes in diet, weight, hydration, and other medications. These factors can affect eye health independently.

The Inc. report describes two studies linking GLP-1 drugs with unexpected health problems, but the supplied summary does not identify the specific findings or provide enough detail to assess causation (Source 1).

A well-designed study should compare similar patients, account for diabetes severity, measure eye health before treatment, and follow participants long enough to identify meaningful differences. Evidence becomes stronger when randomized trials, observational studies, case reports, specialist assessments, and regulatory reviews produce consistent findings.

When to Seek Prompt Medical Care

Contact an eye-care professional or seek urgent medical care for:

• Sudden vision loss in one eye.
• A new dark, blurry, or missing area in the visual field.
• New flashes of light.
• A sudden increase in floaters.
• A curtain-like shadow across vision.
• Severe eye pain or sudden redness.
• New double vision.
• Major difficulty focusing.
• Sudden distortion of straight lines.

Some eye conditions are time-sensitive. When seeking care, provide the medication name and dose, the date of the last injection, other medications, the time symptoms began, and whether one or both eyes are affected.

Do not assume blurry vision is caused by dehydration, blood sugar changes, or the medication itself.

What People Taking Ozempic or Wegovy Should Do

Do not change the dose, skip injections, or stop treatment without contacting the prescribing clinician. If sudden vision loss occurs, seek urgent medical care and tell the clinician that you use semaglutide.

People with diabetes should follow their recommended comprehensive eye-examination schedule. Those with known diabetic retinopathy may need more frequent monitoring. Tell the eye-care professional about semaglutide use, the current dose, recent blood sugar changes, the most recent A1C, changes to diabetes treatment, and previous retinal injections, laser treatment, or eye surgery.

Discuss personal risk factors with the prescribing clinician, including diabetes duration, A1C, retinopathy, blood-pressure control, kidney disease, sleep apnea, smoking, optic-nerve disease, retinal disease, and other medications.

Use only the prescribed dose. Do not share injection pens, even with a new needle. Avoid counterfeit or unapproved compounded products unless a qualified clinician has specifically evaluated and prescribed them. Severe vomiting, persistent diarrhea, or inability to keep fluids down also requires medical advice.

Potential Benefits and Risks

GLP-1 medications can provide important benefits for eligible patients, including improved blood sugar control, weight reduction, and lower cardiovascular risk in specific populations. Treatment decisions should balance expected benefits against individual risks.

A possible eye-related safety signal does not mean that every patient should avoid semaglutide. A ScienceDaily report also describes a possible mental-health benefit associated with Ozempic and Wegovy (Source 5). The supplied summary does not identify the benefit or supporting evidence, so it should not be treated as established treatment guidance.

Ozempic and Wegovy are not replacements for established treatment for depression, anxiety, suicidal thoughts, or other mental-health conditions. People experiencing mental-health symptoms should contact a qualified healthcare professional.

Key Takeaways

• Reports have raised questions about GLP-1 drugs and rare or serious eye problems.
• NAION is a rare vision-loss condition discussed in reporting about GLP-1 medications.
• Diabetic retinopathy may temporarily worsen in some patients when blood sugar improves rapidly.
• Available summaries do not prove that Ozempic or Wegovy directly cause these outcomes.
• Sudden vision changes require prompt medical evaluation.
• Do not stop treatment without speaking with the prescribing clinician.
• Eye-monitoring needs depend on diabetes severity, existing retinopathy, blood sugar changes, and other health conditions.
• Possible mental-health benefits remain separate from established indications and require further evidence.

FAQ

Can Ozempic or Wegovy cause permanent vision loss?

A rare vision-loss condition has been reported in connection with GLP-1 medication use, but an association does not prove that semaglutide caused it. Sudden or unexplained vision changes require urgent medical evaluation.

Should I stop taking Ozempic or Wegovy if I notice blurry vision?

Do not change or stop the medication without contacting the prescribing clinician. Sudden, severe, or one-sided vision changes require prompt eye or emergency care.

Does semaglutide worsen diabetic retinopathy?

The relationship remains under investigation. Rapid improvement in blood sugar may temporarily worsen diabetic retinopathy in some patients, particularly those with existing disease. Maintain recommended eye examinations and discuss retinal history before and during treatment.

How often should people taking GLP-1 drugs have eye exams?

The schedule depends on diabetes status, existing retinopathy, blood sugar control, and personal risk factors. Follow the schedule recommended by a clinician, and seek care sooner if symptoms develop.

Are vision problems common side effects of Ozempic or Wegovy?

Gastrointestinal effects such as nausea, vomiting, diarrhea, and constipation are more commonly reported than serious vision complications. The eye conditions discussed in recent reports appear uncommon or rare, but their exact frequency requires confirmation.

Do GLP-1 medications improve mental health?

Some research has explored possible mental-health benefits, but the evidence and mechanism require careful evaluation. These medications are not established replacements for therapy or prescribed psychiatric treatment.